European pharma stocks flat after Trump slaps 100% tariffs on medicine imports

Stocks listed in Europe closed broadly higher on Friday, as investors assessed the latest trade policy announcements out of the White House.

The pan-European Stoxx 600 index finished the session up 0.8%, with most sectors in positive territory.

The Stoxx Europe 600 Healthcare index saw rocky trade in the morning, oscillating above and below the flatline, before closing flat.

Overnight, President Donald Trump announced that pharmaceutical imports to the U.S. would be hit with 100% tariffs from Oct. 1. Companies who built manufacturing facilities in America would be exempt, Trump said, but only once they started breaking ground on the construction of U.S. plants.

Previously, Trump had threatened to impose tariffs of up to 200% on pharma imports.

Denmark's Zealand Pharma lost 2.4% on Friday, while Novo Nordisk ended 3.5% down. Finland's Orion fell 1.9%.

However, in a note circulated in the wake of Trump's announcements, JP Morgan strategists downplayed the impact the new tariffs would have on the pharmaceutical sector.

The "potential 100% tariff should largely be avoidable with us based manufacturing buildout," they said. "And while there remain a number of unknowns on tonight's announcement … we continue to see a very manageable overall impact from tariffs to our large cap coverage."

Trump also announced on his Truth Social platform on Thursday night that heavy trucks would be slapped with 25% tariffs from next month.

The European Union's own trade policies are also in focus, after German newspaper Handelsblatt reported that the bloc was planning to impose tariffs of up to 50% on Chinese steel in the coming weeks.

Shares of Danish renewables giant Orsted, meanwhile, were last seen 2% lower.

The Financial Times, citing people familiar with the matter, reported on Friday that the crisis-stricken company was in talks to sell a stake in its flagship U.K. project, the Hornsea 3 wind farm, to U.S. asset management giant Apollo.

CNBC has reached out to Orsted and Apollo to comment on the report.